ArchiveAugust 2016

Progressive MS deja vu

Last year we there was a buzz at ECTRIMS about ocrelizumab and this year it may well be Siponimod and its influence on secondary progressive MS. This is to be presented at the late breaking session at ECTRIMS 2016. Is this a game changer? The disruptor for MS pharma, is fingolimod coming-off patent in 2019. With the development of generics the price tumbles (except that MS pharma...

Siponimod saving nerves

Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L, Schubart A, Mandolesi G, Centonze D. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1):207. BACKGROUND:Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis...

Metabolic problems in immune cells can cause autoimmunity

Immunol Cell Biol. 2016 Aug 26. doi: 10.1038/icb.2016.77. [Epub ahead of print] “Immunometabolism and autoimmunity”. Freitag J, Berod L, Kamradt T, Sparwasser T. Abstract A continuous increase in the prevalence of autoimmune diseases is to be expected in the aging societies world-wide. Autoimmune disorders not only cause severe disability and chronic pain, but also lead to...

Safety of daclizumab: 3-year results from the SELECTED study

The paper: Gold, Ralf, et al. “Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.“ BMC Neurology 16.1 (2016): 1. Background: This paper reports early results from a clinical trial evaluating a new drug for relapsing-remitting Multiple Sclerosis (MS)1. The drug – daclizumab – is a...

Pregnancy and Natalizumab

Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M.Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.BMC Neurol. 2016 Aug 24;16(1):150. doi: 10.1186/s12883-016-0674-4. BACKGROUND: Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who...

Does the early bird get the worm in CIS? The 11 year follow-up to the BENEFIT study

The paper: Kappos, et al. “The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.“ Neurology (2016): 10-1212. Background: Multiple Sclerosis (MS) often starts as an individual episode of neurological dysfunction. At this early stage, termed a clinically isolated syndrome (CIS), it is often difficult to predict who will go on to develop...

Controlling flu like symptoms with interferons

Halper J, Centonze D, Newsome SD, Huang D, Robertson C, You X, Sabatella G, Evilevitch V, Leahy L. Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique. Int J MS Care. 2016; 18(4):211-8 BACKGROUND: Flu-like symptoms (FLSs) and injection-site reactions (ISRs) have been...

Cognitive Problems picked up years before diagnosis

Cortese M, Riise T, Bjørnevik K, Bhan A, Farbu E, Grytten N, Hogenesch I, Midgard R, Smith Simonsen C, Telstad W, Ascherio A, Myhr KM.Pre-clinical disease activity in multiple sclerosis- a prospective study on cognitive performance prior to first symptom.Anals Neurology. 2016. doi: 10.1002/ana.24769. [Epub ahead of print] OBJECTIVE: To prospectively investigate potential signs of pre-clinical...

Making MS worse more evidence for a T cell origin

Lisa Ann Gerdes, Kathrin Held, Eduardo Beltrán, Carola Berking, Jörg C. Prinz, Andreas Junker, Julia K. Tietze, Birgit Ertl-Wagner, Andreas Straube, Tania Kümpfel, Klaus Dornmair and Reinhard Hohlfeld CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis Anals Neurol 2016 | DOI: 10.1002/ana.24715 We investigated a patient who developed multiple sclerosis (MS)...

Clonal Expansions in MS Society

de Paula Alves Sousa A, Johnson KR, Nicholas R, Darko S, Price DA, Douek DC, Jacobson S, Muraro PA.Intrathecal T-cell clonal expansions in patients with multiple sclerosis.Ann Clin Transl Neurol. 2016 Apr 20;3(6):422-33. OBJECTIVE:Analysis of the T-cell receptor (TCR) repertoire in the cerebrospinal fluid (CSF) of patients withmultiple sclerosis (MS) can reveal antigen-specific immune responses...

Translate

Categories

Recent Posts

Recent Comments

Archives